



(11) **EP 3 045 176 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 84

(51) Int Cl.:
A61K 31/445^(2006.01) C07D 401/04^(2006.01)

(48) Corrigendum issued on:
12.12.2018 Bulletin 2018/50

(45) Date of publication and mention
of the grant of the patent:
07.11.2018 Bulletin 2018/45

(21) Application number: **15199540.4**

(22) Date of filing: **03.09.2004**

(54) **POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3
DIHYDROISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE**

POLYMORPHE FORMEN VON

3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDIN-2,6-DION

FORMES POLYMORPHES DE 3-(4-AMINO-1-OXO-1,3
DIHYDRO-ISOINDOL-2-YL)-PIPÉRIDINE-2,6-DIONE

(84) Designated Contracting States:
**AT BE CH CZ DE DK ES FI FR GR HU IE IT LI LU
NL PL PT SE TR**

(30) Priority: **04.09.2003 US 499723 P**

(43) Date of publication of application:
20.07.2016 Bulletin 2016/29

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
11185757.9 / 2 425 836
04783095.5 / 1 667 682

(73) Proprietor: **Celgene Corporation**
Summit, NJ 07901 (US)

(72) Inventors:

- **Chen, Roger, Shen-Chu**
Edison, NJ 08820 (US)
- **Muller, George, W.**
Rancho Santa Fe, CA 92067 (US)
- **Jaworsky, Markian, S.**
Hopewell, NJ 08525-1001 (US)

- **Saindane, Manohar, T.**
Decauer, GA 30033 (US)
- **Cameron, Louise**
Nazareth, PA 18064 (US)

(74) Representative: **Jones Day**
Rechtsanwälte, Attorneys-at-Law, Patentanwälte
Prinzregentenstrasse 11
80538 München (DE)

(56) References cited:
US-A1- 2002 045 643

- **CORRAL L G ET AL: "IMMUNOMODULATION BY
THALIDOMIDE AND THALIDOMIDE
ANALOGUES", ANNALS OF THE RHEUMATIC
DISEASES, BRITISH MEDICAL ASSOCIATION,
LONDON, GB, vol. 58, no. SUPPL. 01, 1 January
1999 (1999-01-01), pages I107-I113, XP000861990,
ISSN: 0003-4967**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 045 176 B8

- LENTZSCH S ET AL:
"S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 62, 15 April 2002 (2002-04-15), pages 2300-2305, XP002959459, ISSN: 0008-5472
- CAIRAMR: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163-208, XP001156954, ISSN: 0340-1022, DOI: 10.1007/3-540-69178-2_5